Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is one of the hot penny stocks to invest in now. H.C. Wainwright analyst Joseph ...

Lexicon战略的核心是与诺和诺德公司达成的LX9851全球独家许可协议，这是一种首创的、口服生物利用度高的ACSL5抑制剂，正在开发用于肥胖和体重管理。该协议为Lexicon提供了实质性的财务支持，包括7500万美元的预付款和近期里程碑付款，潜在总付款高达10亿美元，外加分级特许权使用费。

In December 2023, we published a revised edition of the Lexicon as an eBook, which includes updated entries for 104 of the most salient terms we have collected over the past 20 years. Please ...

Little Rock, Ark.-based Lexicon Inc., a provider of construction management, steel fabrication, erection, mechanical ...

THE WOODLANDS, Texas, July 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that data from a study of patients describing the impact of diabetic peripheral neuropathic ...

Find the latest Lexicon Pharmaceuticals, Inc. (LXRX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851. Learn more on LXRX stock here.

THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday ...

Lexicon Pharmaceuticals (NASDAQ: LXRX) plans to cut around 50% of its workforce, or more than 75 jobs, to prioritize commercialization of its drug sotagliflozin, also known as Inpefa and Zynquista.

Lexicon, Inc. has promoted Bryan Glenn to vice president of project management for its Fabrication Group, leveraging his ...

The online community has coined a new term, “Coldplayed,” following a viral video that exposed a CEO’s infidelity. The term ...